桑丁氧化酶抑制剂的最新进展
Zhi-Gang Sun1, Kai-Xiang Wu2, Inam Ullah3
1Central Laboratory, Linyi Central Hospital, No. 17 Jiankang Road, Linyi, 276400, China.
Mini reviews in medicinal chemistry
|September 15, 2023
概括
本综述涵盖了自2015年以来开发的新型山丁氧化酶抑制剂. 这些化合物向尿酸的产生,为高尿血和痛风提供潜在的治疗方法.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 尿酸是纯氨酸代谢的产物,在高度下可以导致高尿血和痛风.
- 丁氧化酶是尿酸生产中的关键酶,使其成为主要药物开发目标.
- 抑制丁氧化酶会降低尿酸水平,为痛风和高尿血症提供治疗策略.
研究的目的:
- 总结一下最近的山丁氧化酶抑制剂的进展.
- 为提供自2015年以来开发的新型抑制剂的概述.
- 为未来的抗痛风药物研究和开发提供见解.
主要方法:
- 2015年以来发表的研究文献综述.
- 基于其化学结构的抑制剂的分类.
- 药物设计,合成和自然产品分离方法的分析.
主要成果:
- 鉴定了来自不同化学类别的新型山丁氧化酶抑制剂.
- 包括天然产品,金胺,三醇,异基胺,石墨烯, furan,库马林,pyrazole,和伊米达衍生物.
- 强调了在发现新治疗剂方面正在进行的努力.
结论:
- 丁氧化酶抑制剂对于管理高尿血和痛风至关重要.
- 多种化学支架显示出开发新抑制剂的前景.
- 持续的研究对于在这一领域的新药发现至关重要.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Antiasthma Drugs: Methylxanthines
266
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
266
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
715
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
715
Antihypertensive Drugs: Vasodilators
565
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
565
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.9K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.9K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
183
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
183


